Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Bullboard Posts
Comment by rtftech16on Dec 06, 2016 10:04pm
227 Views
Post# 25563849

RE:RE:Ratings Upgrade Coming

RE:RE:Ratings Upgrade Coming
cavinsin wrote: Perhaps $ 13 or $ 14 next??  based on what? $ 4-5, for cash on hand. divide cash with outstanding shares. everything else is speculation, I was stock holder of Paladin from mid teens, and got out oround $ 120 , I cant remeber anymore, inherited around 10K shares of GUD.
Let me remind you luck played big role achiving that price, as ENDO shares keept climbing up,
Where is ENDO now?? Do not believe Goodman is smarter then many other CEO's  trying to cash in on someone elses misfortune. will see.


Lol shut the hell up. You have no idea what your talking about. Goodman is on another level. He laughs at the management of Concordia and valeant and has been laughing all along because he knows how stupid their business models are. And now look where they are. Goodman is up there with Charles munger and buffet. Luck = proper preparation and perfect execution. Don't ever forget that. 
Bullboard Posts